Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05456256 · ClinicalTrials.gov registry record · Phase 2

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

A Phase 2 study of Carcinoma, Non-Small Cell Lung and Adenocarcinoma of Lung, sponsored by Lantern Pharma.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
16
Study locations

NCT05456256 is a Phase 2 study of Carcinoma, Non-Small Cell Lung and Adenocarcinoma of Lung that is actively recruiting participants, run by Lantern Pharma. The registered enrollment target is 90 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (72% lower). The trial reports 16 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05456256, a Phase 2 study of Carcinoma, Non-Small Cell Lung and Adenocarcinoma of Lung, is actively recruiting participants, sponsored by Lantern Pharma.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
16
Study locations

Study Summary

The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.

Conditions Studied

Carcinoma, Non-Small Cell Lung Adenocarcinoma of Lung

Interventions

  • DRUG Carboplatin
  • DRUG Pemetrexed
  • DRUG LP-300

Study Locations (16)

Other

  • Chi Mei Medical Center - Tainan
  • National Cheng Kung University Hospital - Tainan
  • Taipei Veterans General Hospital - Taipei
  • TriService General Hospital-Neihu Main Facility - Taipei
  • National Taiwan University Hospital Hsin-Chu Branch - Taoyuan District

California

  • Precision NextGen Oncology and Research Center - Beverly Hills
  • Los Angeles Cancer Network - Fountain Valley
  • Cancer and Blood Specialists Clinic - Los Alamitos

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Texas

  • UT Southwestern Medical Center - Dallas

Virginia

  • Inova Fairfax Hospital - Fairfax

Hokkaido

  • Hokkaido Cancer Center - Sapporo

Kanagawa

  • Kanagawa Cancer Center Hospital - Yokohama

Miyagi

  • Tohoku University Hospital - Sendai

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2023-03-01
Est. Completion 2026-06
Phase Phase 2

Sponsor

Lantern Pharma

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05456256

The ClinicalTrials.gov registry entry for NCT05456256 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (72% lower). The listed sponsor is Lantern Pharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT05456256 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05456256 about?

NCT05456256 is a clinical study titled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma". The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined p...

What is the current status of trial NCT05456256?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2023-03-01. Estimated completion is 2026-06.

What conditions does trial NCT05456256 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Adenocarcinoma of Lung.

What interventions are being tested in trial NCT05456256?

The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), LP-300 (DRUG).

Who is sponsoring clinical trial NCT05456256?

This trial is sponsored by Lantern Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05456256 being conducted?

This trial has 16 study locations across California, Pennsylvania, Texas, Virginia, Hokkaido. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Adenocarcinoma of Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.